Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of QIV-HD in Older Japanese Adults
NCT03233217Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Efluelda in influenza (5 cohorts), sponsored by Sanofi. Primary endpoints: Number of Participants With Immediate Unsolicited Adverse Events at 30 minutes, Number of Participants With Solicited Injection Site and Systemic Reactions at 7 days and 2 more. Started Sep 2017; status: completed.
02
Drugs
Efluelda
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03233217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233217.